{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:57Z","timestamp":1792202577241,"version":"4.4.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 29242"],"award-info":[{"award-number":["IG 29242"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022HB54P9"],"award-info":[{"award-number":["2022HB54P9"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40487-025-00411-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:18:15Z","timestamp":1767874695000},"page":"155-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Toward Personalized Treatment of Urogenital Cancers: The Role of Patient-Derived Organoids"],"prefix":"10.1007","volume":"14","author":[{"given":"Serena","family":"Sagliocchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Musone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Chianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata Gaetana","family":"Cicatiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-3761","authenticated-orcid":false,"given":"Monica","family":"Dentice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"2","key":"411_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 Update on prostate cancer epidemiology and risk factors\u2014a systematic review. Eur Urol. 2023;84(2):191\u2013206.","journal-title":"Eur Urol"},{"issue":"8","key":"411_CR2","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895\u2013904.","journal-title":"World J Urol"},{"issue":"1","key":"411_CR3","first-page":"7","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"411_CR4","first-page":"455","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2024: GLOBOCAN estimates. CA Cancer J Clin. 2024;74(4):455\u201394.","journal-title":"CA Cancer J Clin"},{"key":"411_CR5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41571-023-00761-2","volume":"20","author":"IF Tannock","year":"2023","unstructured":"Tannock IF, et al. Evolution of cancer therapy: a historical perspective. Nat Rev Clin Oncol. 2023;20:423\u201339.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6127","key":"411_CR6","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, et al. Cancer genome landscapes. Science. 2013;339(6127):1546\u201358.","journal-title":"Science"},{"issue":"5","key":"411_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"2","key":"411_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63\u201389.","journal-title":"World J Oncol"},{"issue":"1","key":"411_CR9","volume":"5","author":"MB Culp","year":"2022","unstructured":"Culp MB, et al. Prostate cancer incidence and mortality trends. JAMA Netw Open. 2022;5(1):e2141398.","journal-title":"JAMA Netw Open"},{"key":"411_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, et al. Emerging mechanisms of resistance to androgen receptor inhibitors. Nat Rev Cancer. 2015;15:701\u201311.","journal-title":"Nat Rev Cancer"},{"key":"411_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2016.01.036","volume":"70","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Prostate cancer clinical outcomes and therapeutic strategies. Eur Urol. 2016;70:71\u201383.","journal-title":"Eur Urol"},{"key":"411_CR12","first-page":"211","volume":"6","author":"G Attard","year":"2016","unstructured":"Attard G, et al. Targeting the androgen receptor pathway in prostate cancer. Cancer Discov. 2016;6:211\u201322.","journal-title":"Cancer Discov"},{"issue":"1","key":"411_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s11658-025-00725-7","volume":"30","author":"DC Maresca","year":"2025","unstructured":"Maresca DC, et al. Circulating innate lymphoid cells are dysregulated in patients with prostate cancer. Cell Mol Biol Lett. 2025;30(1):48.","journal-title":"Cell Mol Biol Lett"},{"key":"411_CR14","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/j.1464-410X.2011.10325.x","volume":"108","author":"M Kirby","year":"2011","unstructured":"Kirby M, et al. Characterizing advanced prostate cancer. BJU Int. 2011;108:1242\u20138.","journal-title":"BJU Int"},{"issue":"10","key":"411_CR15","first-page":"624","volume":"20","author":"JS De Bono","year":"2023","unstructured":"De Bono JS, Attard G, Antonarakis ES, Chi KN, Mateo J. PARP inhibitors alone or in combination for prostate cancer. Nat Rev Urol. 2023;20(10):624\u201342.","journal-title":"Nat Rev Urol"},{"key":"411_CR16","doi-asserted-by":"publisher","first-page":"175883592312213","DOI":"10.1177\/17588359231221337","volume":"16","author":"MT Bourlon","year":"2024","unstructured":"Bourlon MT, Wang JS, Mateo J, Sweeney CJ. Development of PARP inhibitors in advanced prostate cancer. Ther Adv Med Oncol. 2024;16:17588359231221336.","journal-title":"Ther Adv Med Oncol"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, et al. Aberrant signaling in prostate cancer. Cancer Cell. 2011;19:575\u201386.","journal-title":"Cancer Cell"},{"key":"411_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"411_CR19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, et al. Molecular characterization of neuroendocrine prostate cancer. Nat Med. 2016;22:308\u201318.","journal-title":"Nat Med"},{"key":"411_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","volume":"162","author":"D Robinson","year":"2015","unstructured":"Robinson D, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;162:454\u201369.","journal-title":"Cell"},{"key":"411_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100296","volume":"8","author":"AG Cicatiello","year":"2025","unstructured":"Cicatiello AG, Musone M, Imperatore S, et al. Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis. J Liq Biopsy. 2025;8:100296.","journal-title":"J Liq Biopsy"},{"key":"411_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100305","volume":"9","author":"F Crocetto","year":"2025","unstructured":"Crocetto F, Musone M, Chianese S, et al. Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions. J Liq Biopsy. 2025;9:100305.","journal-title":"J Liq Biopsy"},{"key":"411_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100310","author":"F Crocetto","year":"2025","unstructured":"Crocetto F, et al. Liquid biopsy: current advancements in clinical practice for bladder cancer. J Liq Biopsy. 2025. https:\/\/doi.org\/10.1016\/j.jlb.2025.100310.","journal-title":"J Liq Biopsy"},{"key":"411_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.07.034","author":"P Pisapia","year":"2025","unstructured":"Pisapia P, et al. Liquid biopsy testing in urological cancers: focus on urine. Urol Oncol Semin Orig Investig. 2025. https:\/\/doi.org\/10.1016\/j.urolonc.2025.07.034.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"22","key":"411_CR25","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3390\/cells11223632","volume":"11","author":"A Van Hemelryk","year":"2022","unstructured":"Van Hemelryk A, Tomljanovic I, de Ridder CMA, et al. Patient-derived xenografts and organoids recapitulate castration-resistant prostate cancer with sustained androgen receptor signaling. Cells. 2022;11(22):3632.","journal-title":"Cells"},{"key":"411_CR26","volume":"532","author":"C Miro","year":"2025","unstructured":"Miro C, et al. Thyroid hormone and androgen crosstalk in prostate cancer microenvironment. Mol Cell Endocrinol. 2025;532:215581.","journal-title":"Mol Cell Endocrinol"},{"key":"411_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2025.03.001","volume":"112","author":"S Sagliocchi","year":"2025","unstructured":"Sagliocchi S, et al. Tumor microenvironment and obesity-cancer link. Semin Cancer Biol. 2025;112:36\u201342.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"411_CR28","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000543983","volume":"109","author":"R Liu","year":"2025","unstructured":"Liu R, Zhang Y, Zhou Z, et al. Patient-derived bladder cancer organoids: model construction and drug sensitivity testing. Urol Int. 2025;109(5):478\u201386.","journal-title":"Urol Int"},{"key":"411_CR29","first-page":"1392210","volume":"15","author":"L Zhu","year":"2024","unstructured":"Zhu L, Li H, Huang Y, et al. Thyroid hormone receptor crosstalk with androgen signaling in the prostate cancer microenvironment. Front Endocrinol. 2024;15:1392210.","journal-title":"Front Endocrinol"},{"issue":"2","key":"411_CR30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/cancers16020412","volume":"16","author":"X Mao","year":"2024","unstructured":"Mao X, Chen Y, Zhou Q, et al. Obesity-driven inflammatory signaling modulates tumor progression in prostate cancer organoid models. Cancers. 2024;16(2):412.","journal-title":"Cancers"},{"issue":"2","key":"411_CR31","first-page":"245","volume":"19","author":"M Khalili","year":"2025","unstructured":"Khalili M, Torabinejad S, Rezaei-Tavirani M, et al. Network-based modeling reveals key signaling pathways in castration-resistant prostate cancer. Mol Oncol. 2025;19(2):245\u201358.","journal-title":"Mol Oncol"},{"issue":"3","key":"411_CR32","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0228","volume":"12","author":"S Torabinejad","year":"2023","unstructured":"Torabinejad S, et al. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications. Eur Thyroid J. 2023;12(3):e220228.","journal-title":"Eur Thyroid J"},{"issue":"12","key":"411_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41580-018-0075-1","volume":"19","author":"S Zhao","year":"2022","unstructured":"Zhao S, Ramaswamy A, Ghosh S, Gupta S, Kaipparettu BA. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer. Nat Rev Urol. 2022;19(12):808\u201325.","journal-title":"Nat Rev Urol"},{"key":"411_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176\u201387.","journal-title":"Cell"},{"issue":"5","key":"411_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/biom15050625","volume":"15","author":"WA Kwon","year":"2025","unstructured":"Kwon WA, Joung JY. Precision targeting in metastatic prostate cancer: molecular insights to therapeutic frontiers. Biomolecules. 2025;15(5):625.","journal-title":"Biomolecules"},{"issue":"8","key":"411_CR36","doi-asserted-by":"publisher","first-page":"EVIDoa2300023","DOI":"10.1056\/EVIDoa2300023","volume":"2","author":"DE Spratt","year":"2023","unstructured":"Spratt DE, Tang S, et al. Artificial intelligence predictive model for hormone therapy use in prostate cancer. NEJM Evid. 2023;2(8):EVIDoa2300023.","journal-title":"NEJM Evid"},{"issue":"3","key":"411_CR37","first-page":"176","volume":"7","author":"MG Cumberbatch","year":"2018","unstructured":"Cumberbatch MG, et al. Epidemiology of bladder cancer: a global perspective. Transl Androl Urol. 2018;7(3):176\u201385.","journal-title":"Transl Androl Urol"},{"key":"411_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341.","journal-title":"Eur Urol"},{"key":"411_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"JA Witjes","year":"2017","unstructured":"Witjes JA, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462\u201375.","journal-title":"Eur Urol"},{"key":"411_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, et al. EAU guidelines on non-muscle-invasive bladder cancer. Eur Urol. 2017;71:447\u201361.","journal-title":"Eur Urol"},{"key":"411_CR41","first-page":"e567","volume":"21","author":"JA Witjes","year":"2020","unstructured":"Witjes JA, et al. Advances in intravesical therapy for bladder cancer. Lancet Oncology. 2020;21:e567\u201378.","journal-title":"Lancet Oncology"},{"key":"411_CR42","first-page":"1226","volume":"181","author":"BWG van Rhijn","year":"2009","unstructured":"van Rhijn BWG, et al. Clinical implications of bladder cancer progression. J Urol. 2009;181:1226\u201333.","journal-title":"J Urol"},{"key":"411_CR43","first-page":"421","volume":"228","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl G, et al. Molecular taxonomy of bladder cancer. J Pathol. 2012;228:421\u201330.","journal-title":"J Pathol"},{"key":"411_CR44","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"W Choi","year":"2014","unstructured":"Choi W, et al. Basal and luminal subtypes of bladder cancer. Proc Natl Acad Sci U S A. 2014;111:3110\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"411_CR45","first-page":"457","volume":"29","author":"G Wang","year":"2022","unstructured":"Wang G, Oliveira RB, Lerner SP, Kamat AM. Predictive biomarkers of response to Bacillus Calmette-Gu\u00e9rin immunotherapy and Bacillus Calmette-Gu\u00e9rin failure for non muscle invasive bladder cancer. Int J Urol. 2022;29(5):457\u201368.","journal-title":"Int J Urol"},{"key":"411_CR46","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/cancers11121925","volume":"11","author":"C Rausch","year":"2019","unstructured":"Rausch C, et al. Limitations of preclinical bladder cancer models. Cancers. 2019;11:1925.","journal-title":"Cancers"},{"key":"411_CR47","first-page":"11394076","volume":"13","author":"Z Chen","year":"2023","unstructured":"Chen Z, Dong Z, Yang Z, et al. Contemporary molecular markers for predicting systemic treatment response in urothelial bladder cancer: a narrative review. Front Oncol. 2023;13:11394076.","journal-title":"Front Oncol"},{"key":"411_CR48","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1038\/s41467-022-33054-w","volume":"13","author":"YT Chen","year":"2022","unstructured":"Chen YT, Shapiro B, Lee C, et al. Urinary cell-free DNA and extracellular vesicle RNA analysis for non-invasive detection and surveillance of urothelial carcinoma. Nat Commun. 2022;13:5524.","journal-title":"Nat Commun"},{"key":"411_CR49","first-page":"1426","volume":"24","author":"SH Lee","year":"2018","unstructured":"Lee SH, et al. Patient-derived organoids for bladder cancer research. Nat Med. 2018;24:1426\u201334.","journal-title":"Nat Med"},{"key":"411_CR50","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, et al. Patient-derived organoids model treatment response. Science. 2018;359:920\u20136.","journal-title":"Science"},{"issue":"1","key":"411_CR51","volume":"24","author":"W Chen","year":"2024","unstructured":"Chen W, Zhang W, Yu J, Xu C, Xu Y, Xiang Y. Diagnostic and prognostic potential of exosome non-coding RNAs in bladder cancer: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):290.","journal-title":"BMC Cancer"},{"key":"411_CR52","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933\u201345.","journal-title":"Cell"},{"issue":"1","key":"411_CR53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.bbcan.2018.06.003","volume":"1870","author":"DJ Sanchez","year":"2018","unstructured":"Sanchez DJ, Simon MC. Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochim Biophys Acta Rev Cancer. 2018;1870(1):23\u201331.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"411_CR54","first-page":"298","volume":"128","author":"WG Kaelin Jr","year":"2017","unstructured":"Kaelin WG Jr, The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc. 2017;128:298\u2013307.","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"19","key":"411_CR55","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, CheckMate 025 Investigators, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313 (Epub 2015 Sep 25).","journal-title":"N Engl J Med"},{"issue":"10","key":"411_CR56","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","volume":"31","author":"BI Rini","year":"2025","unstructured":"Rini BI, et al. Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase\u00a03 KEYNOTE-426 trial. Nat Med. 2025;31(10):3475\u201384.","journal-title":"Nat Med"},{"issue":"1","key":"411_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5483\/BMBRep.2022-0200","volume":"56","author":"E Seo","year":"2023","unstructured":"Seo E, Kang M. Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers. BMB Rep. 2023;56(1):24\u201331.","journal-title":"BMB Rep"},{"issue":"7","key":"411_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.970","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med. 2022;12(7):e970.","journal-title":"Clin Transl Med"},{"issue":"18","key":"411_CR59","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.3390\/cancers14184359","volume":"14","author":"E Francini","year":"2022","unstructured":"Francini E, et al. Circulating cell-free DNA in renal cell carcinoma: the new era of precision medicine. Cancers (Basel). 2022;14(18):4359.","journal-title":"Cancers (Basel)"},{"issue":"13","key":"411_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902060","volume":"3","author":"B Wang","year":"2022","unstructured":"Wang B, Xue Y, Zhai W. Integration of tumor microenvironment in patient-derived organoid models help define precision medicine of renal cell carcinoma. Front Immunol. 2022;3(13):902060.","journal-title":"Front Immunol"},{"issue":"12","key":"411_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7432","volume":"13","author":"RT Tse","year":"2024","unstructured":"Tse RT, et al. The establishment of kidney cancer organoid line in drug testing. Cancer Med. 2024;13(12):e7432.","journal-title":"Cancer Med"},{"key":"411_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-cancerbio-030518-055702","volume":"3","author":"H Clevers","year":"2019","unstructured":"Clevers H, Tuveson D. Organoid models for cancer research. Annu Rev Cancer Biol. 2019;3:333\u201354.","journal-title":"Annu Rev Cancer Biol"},{"issue":"5","key":"411_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molmed.2017.02.007","volume":"23","author":"D Dutta","year":"2017","unstructured":"Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23(5):393\u2013410.","journal-title":"Trends Mol Med"},{"issue":"1","key":"411_CR64","first-page":"55","volume":"7","author":"RR Kotecha","year":"2024","unstructured":"Kotecha RR, O\u2019Donnell PH, et al. Patient-derived organoids as functional precision oncology tools in urothelial carcinoma. Eur Urol Oncol. 2024;7(1):55\u201367.","journal-title":"Eur Urol Oncol"},{"key":"411_CR65","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1242\/dev.092270","volume":"140","author":"CM Ramsden","year":"2013","unstructured":"Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: past, present and future. Development. 2013;140:2576\u201385.","journal-title":"Development"},{"key":"411_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2159-8290.CD-16-1154","volume":"7","author":"C Pauli","year":"2017","unstructured":"Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462\u201377.","journal-title":"Cancer Discov"},{"issue":"9","key":"411_CR67","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","volume":"24","author":"F Weeber","year":"2017","unstructured":"Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017;24(9):1092\u2013100.","journal-title":"Cell Chem Biol"},{"key":"411_CR68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature09941","volume":"472","author":"M Eiraku","year":"2011","unstructured":"Eiraku M, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature. 2011;472:51\u20136.","journal-title":"Nature"},{"key":"411_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.stemcr.2016.12.008","volume":"8","author":"M Mandai","year":"2017","unstructured":"Mandai M, et al. iPSC-derived retina transplants improve vision in rd1 end-stage retinal-degeneration mice. Stem Cell Rep. 2017;8:69\u201383.","journal-title":"Stem Cell Rep"},{"key":"411_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119744","volume":"232","author":"V Brancato","year":"2020","unstructured":"Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Could 3D models of cancer enhance drug screening? Biomaterials. 2020;232:119744.","journal-title":"Biomaterials"},{"key":"411_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","volume":"13","author":"G Schwank","year":"2013","unstructured":"Schwank G, et al. Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653\u20138.","journal-title":"Cell Stem Cell"},{"key":"411_CR72","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/d41586-018-03841-x","volume":"556","author":"CJ Kuo","year":"2018","unstructured":"Kuo CJ, Curtis C. Organoids reveal cancer dynamics. Nature. 2018;556:441\u20132.","journal-title":"Nature"},{"key":"411_CR73","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.stem.2018.02.010","volume":"22","author":"SK Muthuswamy","year":"2018","unstructured":"Muthuswamy SK. Organoid models of cancer explode with possibilities. Cell Stem Cell. 2018;22:290\u20131.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"411_CR74","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18(7):407\u201318. https:\/\/doi.org\/10.1038\/s41568-018-0007-6.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"411_CR75","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9(1):2404. https:\/\/doi.org\/10.1038\/s41467-018-04495-z.","journal-title":"Nat Commun."},{"issue":"3","key":"411_CR76","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","volume":"130","author":"BJ Viergever","year":"2024","unstructured":"Viergever BJ, Raats DAE, Geurts V, et al. Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation. Br J Cancer. 2024;130(3):369\u201379.","journal-title":"Br J Cancer"},{"issue":"10","key":"411_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116352","volume":"44","author":"R Dolgos","year":"2025","unstructured":"Dolgos R, et al. Single-cell analysis uncovers preserved prostate cancer lineages and universally altered pathways in Matrigel-free patient-derived organoids. Cell Rep. 2025;44(10):116352.","journal-title":"Cell Rep"},{"issue":"1","key":"411_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-021-01426-3","volume":"20","author":"S Pamarthy","year":"2021","unstructured":"Pamarthy S, Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer. 2021;20(1):125.","journal-title":"Mol Cancer"},{"issue":"5","key":"411_CR79","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","volume":"86","author":"NM Merrill","year":"2024","unstructured":"Merrill NM, et al. Integrative drug screening and multiomic characterization of patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response. Eur Urol. 2024;86(5):434\u201344.","journal-title":"Eur Urol"},{"issue":"2","key":"411_CR80","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost J, Karthaus WR, Gao D, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016;11(2):347\u201358.","journal-title":"Nat Protoc"},{"issue":"7765","key":"411_CR81","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","volume":"571","author":"EJ Adams","year":"2019","unstructured":"Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408\u201312.","journal-title":"Nature"},{"issue":"1","key":"411_CR82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.","journal-title":"Nat Rev Dis Primers"},{"key":"411_CR83","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updates. 2023;68:100962.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"411_CR84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/ng1061","volume":"33","author":"L Dyrskj\u00f8t","year":"2003","unstructured":"Dyrskj\u00f8t L, Thykjaer T, Kruh\u00f8ffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33(1):90\u20136. https:\/\/doi.org\/10.1038\/ng1061.","journal-title":"Nat Genet."},{"issue":"5","key":"411_CR85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","volume":"32","author":"CD Hurst","year":"2017","unstructured":"Hurst CD, Alder O, Platt FM, et al. Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. Cancer Cell. 2017;32(5):701-715.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.08.005.","journal-title":"Cancer Cell."},{"issue":"5","key":"411_CR86","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.3390\/ijms15057139","volume":"15","author":"M Kang","year":"2014","unstructured":"Kang M, Kim HH, Han YM. Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free system. Int J Mol Sci. 2014;15(5):7139\u201357.","journal-title":"Int J Mol Sci"},{"issue":"7341","key":"411_CR87","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09851","volume":"472","author":"K Shin","year":"2011","unstructured":"Shin K, Lee J, Guo N, et al. Hedgehog\/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472(7341):110\u20134.","journal-title":"Nature"},{"issue":"2","key":"411_CR88","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee SH, Hu W, Matulay JT, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(2):515-28.e17.","journal-title":"Cell"},{"key":"411_CR89","volume":"5","author":"LA Garraway","year":"2013","unstructured":"Garraway LA, Verweij J. Precision oncology: the path forward. Sci Transl Med. 2013;5:188ps9.","journal-title":"Sci Transl Med"},{"key":"411_CR90","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135.","journal-title":"N Engl J Med"},{"key":"411_CR91","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.2016.1654","volume":"315","author":"EA Ashley","year":"2016","unstructured":"Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2016;315:1449\u201350.","journal-title":"JAMA"},{"key":"411_CR92","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","volume":"520","author":"NJ Schork","year":"2015","unstructured":"Schork NJ. Personalized medicine: time for one-person trials. Nature. 2015;520:609\u201311.","journal-title":"Nature"},{"key":"411_CR93","first-page":"469","volume":"16","author":"R Dienstmann","year":"2017","unstructured":"Dienstmann R, et al. Precision oncology: translating the genome into the clinic. Nat Rev Drug Discov. 2017;16:469\u201378.","journal-title":"Nat Rev Drug Discov"},{"key":"411_CR94","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2016.05.082","volume":"165","author":"H Clevers","year":"2016","unstructured":"Clevers H. Modeling development and disease with organoids. Cell. 2016;165:1586\u201397.","journal-title":"Cell"},{"key":"411_CR95","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"411_CR96","first-page":"512","volume":"6","author":"J Smith","year":"2025","unstructured":"Smith J, et al. Pan-cancer PDOs preserve tumor heterogeneity and uncover therapeutic vulnerabilities. Nat Cancer. 2025;6(4):512\u201328.","journal-title":"Nat Cancer"},{"issue":"2","key":"411_CR97","first-page":"85","volume":"10","author":"S Tan","year":"2024","unstructured":"Tan S, et al. Breaking the mold: 3D cell cultures reshaping the future of cancer modelling. Trends Cancer Res. 2024;10(2):85\u2013101.","journal-title":"Trends Cancer Res"},{"issue":"2","key":"411_CR98","volume":"4","author":"X Li","year":"2024","unstructured":"Li X, et al. Quantitatively evaluating interactions between patient-derived organoids and autologous immune cells by microfluidic chip. Cell Rep Methods. 2024;4(2):100285.","journal-title":"Cell Rep Methods"},{"issue":"1","key":"411_CR99","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13046-023-02800-3","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance in pancreatic cancer. J Exp Clin Cancer Res. 2023;42(1):220.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"411_CR100","first-page":"421","volume":"48","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, et al. Organoid models in bladder cancer: from bench to bedside? Cell Oncol. 2025;48(5):421\u201339.","journal-title":"Cell Oncol"},{"key":"411_CR101","doi-asserted-by":"publisher","first-page":"1164067","DOI":"10.3389\/fendo.2023.1164067","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Diao L, Zhang C, et al. Use of PARP inhibitors in prostate cancer: from specific to broader application. Front Endocrinol (Lausanne). 2023;14:1164067. https:\/\/doi.org\/10.3389\/fendo.2023.1164067.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"411_CR102","first-page":"102","volume":"17","author":"E Slootweg","year":"2025","unstructured":"Slootweg E, et al. PARP inhibition in prostate and bladder cancer: emerging biomarkers and clinical trials update. Cancers. 2025;17(1):102.","journal-title":"Cancers"},{"issue":"11","key":"411_CR103","first-page":"693","volume":"20","author":"L Chen","year":"2023","unstructured":"Chen L, et al. Precision oncology options in urological cancers: targeted and immunotherapeutic approaches. Nat Rev Urol. 2023;20(11):693\u2013709.","journal-title":"Nat Rev Urol"},{"issue":"17","key":"411_CR104","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/cells12172188","volume":"12","author":"S Walz","year":"2023","unstructured":"Walz S, Pollehne P, Geng R, et al. A protocol for organoids from the urine of bladder cancer patients. Cells. 2023;12(17):2188.","journal-title":"Cells"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00411-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00411-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:04:16Z","timestamp":1773673456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00411-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00411-w","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests. All authors (Serena Sagliocchi, Michele Musone, Stefano Chianese, Annunziata Gaetana Cicatiello, Silvia Del Mastro, Francesco Del Giudice, Monica Dentice and Felice Crocetto) have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}